Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
暂无分享,去创建一个
E. Van Cutsem | H. Kalofonos | M. Peeters | S. Cascinu | S. Siena | R. Amado | M. Wolf | A. Sobrero | A. Hendlisz | G. Devercelli | Rafael G. Amado
[1] A. Jemal,et al. Global Cancer Statistics , 2011 .
[2] Daniel J. Freeman,et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] W. Scheithauer,et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] E. Van Cutsem,et al. Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab , 2007, British Journal of Cancer.
[5] R. Amado,et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice , 2007, Nature Biotechnology.
[6] M. Moroni,et al. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Marc Peeters,et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] Manuel Hidalgo,et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] F. Ciardiello,et al. Cetuximab dose-escalation in mCRC patients with no or slight skin reactions on standard treatment (EVEREST). , 2007 .
[10] S. Kaasa,et al. Methods for handling missing data in palliative care research , 2006, Palliative medicine.
[11] M. Lacouture. Mechanisms of cutaneous toxicities to EGFR inhibitors , 2006, Nature Reviews Cancer.
[12] Ma Dong,et al. Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal Cancer , 2006 .
[13] F. Ciardiello,et al. Cetuximab dose-escalation study in patients with metastatic colorectal cancer (MCRC) with no or slight skin reactions on cetuximab standard dose treatment (Everest): Preliminary PK and efficacy data of a randomized study , 2006 .
[14] R. Perez-soler,et al. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[16] John E. Brazier,et al. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D , 2005, Quality of Life Research.
[17] Armando Santoro,et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. , 2004, The New England journal of medicine.
[18] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[19] Neal J Meropol,et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Figlin,et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. , 2004, International journal of radiation oncology, biology, physics.
[21] D. Fairclough. Design and analysis of quality of life studies in clinical trials , 2002, Quality of Life Research.
[22] David Cella,et al. What Are the Most Important Symptom Targets When Treating Advanced Cancer? A Survey of Providers in the National Comprehensive Cancer Network (NCCN) , 2003, Cancer investigation.
[23] Frank de Charro,et al. The Measurement and Valuation of Health Status Using EQ-5D: A European Perspective , 2003, Springer Netherlands.
[24] Diane Lynn Fairclough,et al. Design and analysis of quality of life studies in clinical trials : interdisciplinary statistics , 2002 .
[25] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[26] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[28] O. Bouché,et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Lotz,et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. , 1999, European journal of cancer.
[30] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[31] A. Finlay,et al. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.
[32] D. Osoba,et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.
[33] N. Lemoine,et al. Immunohistochemical detection of the epidermal growth factor receptor in paraffin‐embedded human tissues , 1991, The Journal of pathology.